If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful starting point is understanding what the current market price might be ...
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...
Discover the world of Recursive Self-Improvement (RSI) in AI. From I.J. Good's intelligence explosion to modern self-healing code and clinical applications, explore who is developing it, how it works, ...
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...
Recursion Pharmaceuticals granted inducement RSU awards to 17 new employees under its 2024 Inducement Equity Incentive Plan. The awards are tied to recent hiring activity and are intended as ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) falls more steeply than broader market: What investors need to know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...
We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...
The concept of a meme stock was born about five years ago. It refers to a publicly traded company that gains substantial market value practically overnight (sometimes literally) due to significant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results